Xtalpi Joins $46 Million Round for PhoreMost in Drug Discovery Tie-Up

XtalPi, a Boston-Shenzhen AI drug discovery company, participated in the $46 million B funding round for PhoreMost, a UK company with a novel drug discovery platform. Both XtalPi and PhoreMost claim expertise in drug discovery for targets considered undruggable, and they expect their platforms may offer additional benefits when used together. The B round was led by BGF, with participation from XtalPi and other new and existing investors. Dr. Alan Jiang, XtalPi's Chief Strategy Officer will join PhoreMost's Board. More details.... Share this with colleagues: // //